tirzepatide and bone loss Tirzepatide, a dual GLP-1 GIP receptor agonist, promotes in obese mice via gut microbial-related metabolites Weight-Loss Medications, Joint Pain, and

Semaglutide use after gallbladder removal requires careful medical oversight due to altered bile acid metabolism and increased gastrointestinal sensitivity

Wegovy (semaglutide 2.4 mg) ~15% mean weight loss at ~68 weeks Strongest CV outcomes and long-term safety base Still a blockbuster but clearly behind on magnitude

Manufacturing is done at an FDA registered facility which complies with NSF and GMP guidelines

with hyperglycemia

Our medical weight loss center in Southlake will motivate, encourage, and boost your confidence all while you reach your weight loss goals!

Our clinical team works alongside the member's prescriber to manage GLP-1 use, support tapering when biology indicates the member is ready, and stay engaged after discontinuation so progress holds